

3 August 2018

## 2018/19 Invitation to Tender

PHARMAC is seeking feedback from medical groups, DHB hospital pharmacies and other interested parties on:

- A proposal to tender certain pharmaceuticals for sole supply; and
- The draft process and terms and conditions for the 2018/19 Invitation to Tender (2018/19 Tender).

PHARMAC welcomes all feedback on the draft 2018/19 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC and would be considered by the PHARMAC Board (or its Delegate, where applicable) prior to making a decision on this proposal.

**ALL RESPONSES ARE DUE BY 5 PM, THURSDAY 6 SEPTEMBER 2018**

Feedback should be provided by submitting an email or letter to the Tender Analysts:

Email: [tender@pharmac.govt.nz](mailto:tender@pharmac.govt.nz)

Letter: Tender Analysts  
PHARMAC  
PO Box 10-254  
Wellington 6143

DDI: Heather Milne (04) 830 2658

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.

### Details of the proposed 2018/19 Tender

In accordance with PHARMAC's objective (to secure, for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided), PHARMAC is

consulting on a proposal to tender certain pharmaceuticals for Sole Supply Status to community pharmacies and/or Hospital Supply Status for supply to DHB hospital pharmacies.

Attached to this letter (as Schedule Two) is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply and/or Hospital Supply Status. Pharmaceuticals are sorted into therapeutic groups and then listed alphabetically in each group by chemical, form and strength. Each pharmaceutical has a 'C' and/or 'H' next to it to indicate whether it is proposed to be tendered for community and/or hospital supply.

In general, the proposed 2018/19 Tender process would be similar to the 2017/18 Tender. A copy of the draft 2018/19 Invitation to Tender is available on our website: [www.pharmac.health.nz](http://www.pharmac.health.nz), or by contacting PHARMAC.

We are seeking feedback on the approach outlined in the following pages, in particular on:

- The proposed tender process and timeline;
- The actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule Two, including the impact of a brand switch on patients and clinical staff; and
- For hospital pharmaceuticals, your views on the appropriate Discretionary Variance (DV) Limit for each pharmaceutical, in the event you consider a 1% DV Limit to be clinically unacceptable.

## **Background**

Since 1997 PHARMAC has been using the strategy of tendering pharmaceuticals for sole supply of pharmaceuticals for a fixed period of time. Regular tendering has proven to be an effective way to encourage competition among suppliers of pharmaceuticals. As in the past, the community and hospital tender processes would be run in unison, however, the pharmaceutical list for community and hospital supply may be different.

## **Key Aspects of Awarding a Tender for Community Pharmaceuticals:**

- For community pharmaceuticals, the tender winning brand would be the only subsidised brand for up to approximately 3 years. The Sole Subsidised Supply period would conclude on 30 June 2022 for all Tenders awarded from the 2018/19 Tender.
- No other brand of the pharmaceutical would be listed (or subsidised) in Section B of the Pharmaceutical Schedule during the Sole Subsidised Supply period.
- Other brands could continue to be marketed, sold and dispensed during the Sole Subsidised Supply Status period, but they would not receive a subsidy.
- Any pharmaceutical that currently carries a manufacturer's surcharge (that is, the additional patient charge above that of the patient co-payment) would become fully subsidised if a tender was awarded for that pharmaceutical.

## **Key Aspects of Awarding a Tender for DHB Hospital Pharmaceuticals:**

- For DHB hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (subject to any allowance for alternative

brands under the agreed DV Limits) for up to approximately 3 years. The Hospital Supply Status period would conclude on 30 June 2022 for all tenders awarded from the 2018/19 Tender.

- No other brand of the pharmaceutical would be listed in Section H of the Pharmaceutical Schedule during the Hospital Supply Status period.

### Key Dates and Timeframes for the 2018/19 Tender:

The proposed timelines for the 2018/19 Tender are as follows:

Date	Event
3 August 2018	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft 2018/19 Tender.
27 August 2018	Final date for receipt of Alternative Commercial Proposals (ACPs) to tendering by PHARMAC.
6 September 2018	Final date for all consultation to be received.
September 2018	PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC's Factors for Consideration, and enters into provisional contracts with suppliers where appropriate.
September 2018	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
September/October 2018	Consultation and decisions on Alternative Commercial Proposals.
Early November 2018	Issuing of the 2018/19 Tender.
14 December 2018	Invitation to Tender closes.
From end of January 2019	Decisions on the first Tender winners announced.

### Contractual obligations for suppliers

A copy of the draft terms and conditions which would form the terms of the 2018/19 Tender contract is available on the PHARMAC website: [www.pharmac.health.nz](http://www.pharmac.health.nz).

### Proposed inclusion of the following provisions in the 2018/19 Invitation to Tender

#### ***Proposal to modify the transition between funded brands in the Schedule***

On 13 July 2018 PHARMAC released a consultation to seek feedback on the proposal to modify the transition between funded brands in the Schedule. The proposal is to remove the reference pricing period during brand changes and would result in the alignment of transition arrangements in the community and DHB hospitals by increasing the transition time in DHB hospitals to five months.

The consultation is available on our website ([www.pharmac.govt.nz/news/consultation-2018-07-13-brand-transition](http://www.pharmac.govt.nz/news/consultation-2018-07-13-brand-transition)) and closes at **5 pm on Friday, 10 August 2018**. Feedback can be emailed to Heather Milne at [heather.milne@pharmac.govt.nz](mailto:heather.milne@pharmac.govt.nz).

If the proposal was to be accepted it would result in changes to Schedule Three and Five in the 2018/19 Tender. Briefly it would result in the Second Transition Period being removed from the 2018/19 Tender which would result in the following changes;

- the Sole Supply Period would be modified to state that it relates to the period beginning on the day after the expiry of the First Transition Period and ending on 30 June 2022.
- the transition period in relation to community supply would be changed from three transition periods to two transition periods, this is the same as the current transition period for hospital supply.
- the subsidy payable for all other brands of the pharmaceutical will remain until the Sole Supply Period begins, this contrasts with the current process which decreases the subsidy to the price of the incoming brand on the first day of the Second Transition Period until the first day of the Sole Supply Period.

### **Additional Special Terms**

---

PHARMAC proposes to include a new schedule in the 2018/19 Tender relating to special terms for the supply of intra-uterine copper device as follows.

You shall provide the following information when submitting a Tender Bid for the Pharmaceutical intra-uterine copper device (“IUCD Tender Item”):

- the size of the IUCD Tender Item, including length and width measurements as well as the diameter of the inserter;
- a description of the material the inserter is made of;
- the duration of the therapeutic effect of the IUCD Tender Item; and
- the metals which are contained in the IUCD Tender Item.

You shall provide the following Resources at no cost for the IUCD Tender Item:

- the provision of education, training and support to healthcare professionals in respect of the use of the IUCD Tender Item.

For the purposes of this clause “Resources” shall include but not be limited to the:

- provision of training materials (DVDs, pamphlets, leaflets, brochures) to healthcare professionals;
- provision of an information sheet explaining the differences between the current brand of intra-uterine device and your IUCD Tender Item; and
- provision of presentations and/or demonstrations on the use of your IUCD Tender Item to patients and/or healthcare professionals.

## Unresolved Tender Bids

PHARMAC would review any unresolved Tender Bids from the 2016/17 Tender and the 2017/18 Tender prior to issuing the 2018/19 Tender, and may close the tender for some of these items, and reissue them as part of the 2018/19 tender. The following Tender Bids remain unresolved, and may potentially be added to the 2018/19 Tender following consultation:

### 2016/17 Invitation to Tender

Chemical Name	Line Item
Amantadine hydrochloride	Cap 100 mg
Benzylpenicillin sodium [Penicillin G]	Inj 3 g
Bupivacaine hydrochloride with adrenaline	Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml sterile pack
Bupivacaine hydrochloride with adrenaline	Inj 5 mg per ml with adrenaline 1:200,000, 20 ml sterile pack
Buprenorphine with naloxone	Tab sublingual 2 mg with naloxone 0.5 mg
Buprenorphine with naloxone	Tab sublingual 8 mg with naloxone 2 mg
Cetirizine hydrochloride	Oral liq 1 mg per ml
Cetrimide	Solution 20% (pack size of 100 ml or less)
Chlorhexidine with ethanol	Soln 2% with ethanol 70%, non-staining (pink) 100 ml
Chlorhexidine with ethanol	Soln 2% with ethanol 70%, non-staining pink (pack size less than 50 ml)

Chemical Name	Line Item
Chlorhexidine with ethanol	Soln 2% with ethanol 70%, staining (red) 100 ml
Chlorhexidine with ethanol	Soln 2% with ethanol 70%, staining red (pack size less than 50 ml)
Ephedrine	Inj 3 mg per ml, 10 ml prefilled syringe
Hyoscine N-butylbromide	Inj 20 mg, 1 ml
Iodine supplement	Tab 150 mcg elemental
Mebeverine hydrochloride	Tab 135 mg
Mercaptopurine	Tab 50 mg
Metoclopramide hydrochloride	Inj 5 mg per ml, 2 ml ampoule
Tenoxicam	Inj 20 mg
Trimethoprim with sulphamethoxazole [Co-trimoxazole]	Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml
Zinc	Paste (pack size 50 g or less)

### 2017/18 Invitation to Tender

Chemical Name	Line Item
Ambrisentan (current access)	Tab 10 mg
Ambrisentan (current access)	Tab 5 mg
Ambrisentan (widened access)	Tab 10 mg
Ambrisentan (widened access)	Tab 5 mg
Amoxicillin clavulanate	Grans for oral liq amoxicillin 400 mg with potassium clavulanate 57 mg per 5 ml
Baclofen	Inj 0.05 mg per ml, 1 ml
Baclofen	Inj 2 mg per ml, 5 ml
Benzoyl peroxide	Soln/Gel 5%

Chemical Name	Line Item
Budesonide (current access)	Cap 3 mg modified release
Budesonide (widened access)	Cap 3 mg modified release
Bumetanide	Tab 1 mg
Bupivacaine hydrochloride	Inj 0.25%, 20 ml sterile pack
Bupivacaine hydrochloride	Inj 0.5%, 10 ml sterile pack
Bupivacaine hydrochloride	Inj 0.5%, 20 ml sterile pack
Calamine	Lothn, BP
Carboplatin	Inj 10 mg per ml, 15 ml

Chemical Name	Line Item
Carboplatin	Inj 10 mg per ml, 45 ml
Chloramphenicol	Inj 1 g
Chlorhexidine gluconate	Crn 1% obstetric
Chlorhexidine gluconate	Lotn 1% obstetric
Chlorhexidine gluconate	Mouthwash 0.2%
Chlorhexidine gluconate	Soln 4%
Colchicine	Tab 500 mcg
Daptomycin	Inj 350 mg- 500 mg
Diclofenac sodium	Eye drops 0.1%
Dorzolamide hydrochloride	Eye drops 2%
Doxorubicin	Inj 200 mg
Efavirenz	Tab 50 mg
Efavirenz	Tab 200 mg
Efavirenz	Tab 600 mg
Epirubicin	Inj 2 mg per ml, 100 ml
Febuxostat	Tab 80 mg
Febuxostat	Tab 120 mg
Ferrous fumarate	Tab 200 mg
Ferrous sulphate with ascorbic acid	Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg
Filgrastim	Inj 120 mg per ml, 0.5 ml prefilled syringe
Filgrastim	Inj 300 mcg per ml, 0.5 ml prefilled syringe
Filgrastim	Inj 480 mcg per ml, 0.5 ml prefilled syringe
Furosemide	Tab 40 mg
Fusidic acid	Crn 2%
Fusidic acid	Oint 2%
Hydrocortisone butyrate	Lipocream 0.1% (pack size greater than 30 g)
Hydrogen peroxide	Crn 1%
Hydrogen peroxide	Soln 3% (10 vol)
Ibuprofen	Tab long-acting 800 mg
Imipenem with cilastatin	Inj 500 mg with cilastatin 500 mg
Irinotecan	Inj 20 mg per ml, 2 ml
Irinotecan	Inj 20 mg per ml, 5 ml
Lidocaine [lignocaine] hydrochloride with adrenaline	Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge
Linezolid	Inj 2 mg per ml, 300 ml

Chemical Name	Line Item
Metaraminol tartrate	Inj 0.5 per ml, 20 ml prefilled syringe
Metaraminol tartrate	Inj 1 mg per ml, 1 ml
Metaraminol tartrate	Inj 1 mg per ml, 10 ml prefilled syringe
Metaraminol tartrate	Inj 10 mg per ml 1 ml
Methadone hydrochloride	Tab 5 mg
Methotrexate	Inj 7.5 mg prefilled syringe
Methotrexate	Inj 10 mg prefilled syringe
Methotrexate	Inj 15 mg prefilled syringe
Methotrexate	Inj 20 mg prefilled syringe
Methotrexate	Inj 25 mg prefilled syringe
Methotrexate	Inj 30 mg prefilled syringe
Midodrine	Tab 2.5 mg
Midodrine	Tab 5 mg
Mitozantrone	Inj 2 mg per ml, 10 ml
Mixed salt solution for eye irrigation	Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 450 ml - 550 ml
Moclobemide	Tab 150 mg
Moclobemide	Tab 300 mg
Nitrofurantoin	Tab 50 mg
Nitrofurantoin	Tab 100 mg
Norethisterone	Tab 5 mg
Oxaliplatin	Inj 50 mg
Oxycodone hydrochloride	Oral liq 1 mg per ml
Pizotifen	Tab 500 mcg
Povidone iodine	Antiseptic soln 10% (pack size 15 ml or less)
Povidone iodine	Antiseptic soln 10% (pack size greater than 100 ml)
Povidone iodine	Antiseptic soln 10% (pack size greater than 15 ml but less

Chemical Name	Line Item
	than or equal to 100 ml)
Povidone iodine	Oint 10%
Rivastigmine	Patch 4.6 mg per 24 hour
Rivastigmine	Patch 9.5 mg per 24 hour
Teicoplanin	Inj 400 mg

Chemical Name	Line Item
Tobramycin	Solution for inhalation 60 mg per ml, 5 ml
Valganciclovir	Tab 450 mg
Zoledronic acid	Inj 4 mg per 100 ml
Zoledronic acid (current access)	Inj 4 mg per 5 ml
Zoledronic acid (widened access)	Inj 4 mg per 5 ml

Should any unresolved Tender Bids be declined prior to the release of the 2018/19 Tender, PHARMAC would consider including those pharmaceuticals in the 2018/19 Tender. Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out in Schedule Two.

### Distribution of Consultation Documents

Although this consultation letter has been widely distributed, should you consider that a particular person, group or agency should receive this letter and/or future tender documents, please feel free to contact PHARMAC or refer it on directly (note, all tender documents and consultations are also available from our website at [www.pharmac.health.nz/news/consultation](http://www.pharmac.health.nz/news/consultation)). We also invite any person or group to contact PHARMAC should you wish to meet to discuss the proposals contained in this consultation letter.

### Schedule Two: Possible pharmaceuticals for tender for sole supply

#### Order of pharmaceuticals in this Schedule

Pharmaceuticals have been listed in groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of these groups, and the corresponding page numbers for your ease of reference. Pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one group.

<b>Therapeutic Group</b>	<b>Page Numbers</b>
Alimentary Tract and Metabolism	9 – 11
Blood and Blood Forming Organs	12
Cardiovascular System	12 – 14
Dermatologicals	14 – 16
Genito-Urinary System	16 – 17
Hormone Preparations – Systemic excluding contraceptives	17 – 18
Infections – Agents for Systemic Use	18 – 21
Musculoskeletal System	21 – 22
Nervous System	22 – 27
Oncology and Immunosuppressants	27 – 29
Respiratory System and Allergies	29 – 30
Sensory Organs	30 – 32
Various	n/a

### Information provided for each pharmaceutical

For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information:

- the current ex-manufacturer subsidy per unit of measure as at 1 July 2018
- the number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2018
- an estimate of the annual community market value at current subsidies (estimated by multiplying the volume of units subsidised in the year ending 30 June 2018 by the relevant listed unit subsidy as at 1 July 2018); and
- comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.

### Explanation of terms, symbols and abbreviations

Most terms and abbreviations used are self-explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

The following table explains the symbols used in the draft pharmaceutical list:

Symbol	Explanation
Underlined	Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2019 unless otherwise stated in the Comments column and a listing of a new brand could only occur after that date.
C	To be tendered for Sole Subsidised Supply Status (community pharmaceuticals).
H	To be tendered for Hospital Supply Status (DHB hospital pharmaceuticals).
PCT	A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC’s Pharmaceutical Cancer Treatments project.
+	PHARMAC has been advised of the existence of a patent.
*	There is no fully funded product available for this line item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP) means a Pharmaceutical, marked with an “@”, for which the supplier of the successful Tender Bid would be required to hold additional stock.
#	A rebate currently exists.



**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Alimentary Tract and Metabolism**

<b>Chemical Name</b>					<b>DV</b>	
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>Limit</b>	<b>Comments</b>
<b>Aluminium hydroxide</b>						
Tab 600 mg	2,300,847	\$288,986	\$0.1256		C H 1%	
<b>Aluminium hydroxide with magnesium hydroxide and simeticone</b>						
Oral liq 200 mg with magnesium hydroxide 200 mg and simeticone 20 mg per 5 ml					H 1%	
Oral liq 400 mg with magnesium hydroxide 400 mg and simeticone 30 mg per 5 ml					H 1%	
<b>Ascorbic acid</b>						
Tab (chewable) 250 mg					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
<u>Tab 100 mg</u>	3,865,804	\$62,626	\$0.0162		C H 1%	
<b>Benzydamine Hydrochloride</b>						
Soln 0.15%	2,122,936	\$38,213	\$0.0180 *		C H 1%	Funding restrictions may apply.
Spray 0.15%					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Funding restrictions may apply.
Spray 0.3%					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Funding restrictions may apply.
<b>Benzydamine hydrochloride with cetylpyridinium chloride</b>						
Lozenge 3 mg with cetylpyridinium chloride					H 1%	
<b>Calcitriol</b>						
Inj 1 mcg per ml, 1 ml					H 1%	
<u>Cap 0.25 mcg</u>	1,269,375	\$126,303	\$0.0995		C H 1%	
<u>Cap 0.5 mcg</u>	492,847	\$90,635	\$0.1839		C H 1%	
Oral liq 1 mcg per ml					C H 1%	
<b>Carboxymethylcellulose</b>						
Oral spray					H 1%	
<b>Dichlorobenzyl alcohol with amylmetacresol</b>						
Lozenge 1.2 mg with amylmetacresol 0.6 mg					H 1%	
<b>Diphenoxylate hydrochloride with atropine sulphate</b>						
Tab 2.5 mg with atropine sulphate 25 mcg					H 1%	
<b>Ferrous Sulphate</b>						
<u>Oral liq 30 mg (6 mg elemental) per ml</u>	6,316,477	\$136,436	\$0.0216		C H 1%	There may be a preference for a child-resistant cap
<b>Fluocortolone Caproate with Fluocortolone Pivalate and Cinchocaine</b>						
Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cinchocaine hydrochloride 5 mg per g	2,413,740	\$510,916	\$0.2117		C H 1%	
Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and cinchocaine hydrochloride 1 mg	614,045	\$136,115	\$0.2217		C H 1%	
<b>Hydrocortisone with Cinchocaine</b>						
Oint 0.05% with cinchocaine hydrochloride 0.05% per g	895,530	\$447,765	\$0.5000 #		C H 1%	
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g	249,226	\$205,611	\$0.8250 #		C H 1%	
<b>Iron sucrose</b>						
Inj 20 mg per ml, 5 ml ampoule					H 1%	
<b>Lactulose</b>						
<u>Oral liq 10 g per 15 ml</u>	195,647,863	\$1,244,320	\$0.0064		C H 1%	Preference for a pack size of 500 ml or similar
<b>Loperamide hydrochloride [split market]</b>						
<u>Cap 2 mg</u>	9,701,128	\$170,934	\$0.0176		C H 1%	PHARMAC reserves the right to award a tender for capsules for the whole market or two separate tenders for capsules and tablets

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Alimentary Tract and Metabolism**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
Line Item					
<b>Loperamide hydrochloride [split market]</b>					
<u>Tab 2 mg</u>	1,861,659	\$50,041	\$0.0269	C H 1%	PHARMAC reserves the right to award a tender for tablets for the whole market or two separate tenders for capsules and tablets
<b>Macrogol 3350</b>					
Powder for oral soln				C H 1%	Not currently listed on the Pharmaceutical Schedule, Special Authority restrictions may apply. Note this is an electrolyte free presentation.
<b>Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride</b>					
Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet				H 1%	
Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet				H 1%	
<b>Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride</b>					
Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg				H 1%	
<b>Macrogol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate</b>					
Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet				H 1%	
<b>Magnesium Hydroxide</b>					
Tab 311 mg				H 1%	
<b>Magnesium Oxide</b>					
Cap 663 mg (400 mg elemental)				H 1%	
<b>Magnesium sulphate</b>					
Inj 0.4 mmol per ml, 250 ml bag				H 1%	
<b>Misoprostol</b>					
<u>Tab 200 mcg</u>	44,191	\$15,283	\$0.3458	C H 1%	
<b>Multivitamins</b>					
<u>Tab (BPC cap strength)</u>	15,597,496	\$163,774	\$0.0105	C H 1%	
<b>Oily Phenol</b>					
Inj 5%, 5 ml				H 1%	
<b>Omeprazole</b>					
Inj 40 mg				H 1%	
<u>Inj 40 mg with diluent</u>	3,137	\$21,319	\$6.7960	C H 1%	
Tab dispersible 20 mg				H 1%	
Powder	8,065	\$68,549	\$8.5000	C H 1%	
<b>Pancreatic enzyme</b>					
Cap pancreatin (175 mg (25,000 lipase, 22,500 U amylase, 1,250 U protease))	66,001	\$62,305	\$0.9440	C H 1%	
Powder pancreatin 60.12 mg (3,600 Ph. Eur. u/amylase, 5,000 Ph. Eur. u/lipase and 200 Ph. Eur./protease)				H 1%	
<b>Pantoprazole</b>					
Inj 40 mg				H 1%	
<u>Tab EC 20 mg</u>	8,808,229	\$212,278	\$0.0241	C H 1%	
<u>Tab EC 40 mg</u>	10,070,485	\$337,361	\$0.0335	C H 1%	
<b>Paraffin</b>					
Enema 133 ml				H 1%	

sole supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Alimentary Tract and Metabolism**

<b>Chemical Name</b>							
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>	
<b>Paraffin</b>							
Oral liquid 1 mg per ml					H 1%		
<b>Pyridoxine hydrochloride</b>							
Inj 100 mg per ml, 1 ml					H 1%		
Inj 100 mg per ml, 30 ml					H 1%		
<b>Retinol</b>							
Cap 25,000 iu					H 1%		
Oral liq 150,000 iu per ml					H 1%		
Tab 10,000 iu					H 1%		
<b>Simeticone</b>							
Oral drops 100 mcg per ml					H 1%		
<b>Sodium Acid Phosphate</b>							
Enema 16% with sodium phosphate 8%	49,715	\$124,288	\$2.5000		C H 1%		
<b>Sodium alginate</b>							
Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml	13,557,170	\$40,672	\$0.0030 *		C H 1%		
Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg	448,827	\$13,465	\$0.0300 *		C H 1%		
<b>Sodium alginate with magnesium alginate</b>							
Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet	1,052,885	\$186,361	\$0.1770 *		C H 1%	Note this product is currently described as 'Alginic acid - sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet' in Section B of the Pharmacuetucial Schedule	
<b>Sodium citrate</b>							
Oral liq 8.8% (300 mmol/l)					H 1%		
<b>Sodium citrate with sodium lauryl sulphoacetate</b>							
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml	431,118	\$230,389	\$0.5344		C H 1%	There would be a preference for a pack size of 50 enemas or fewer	
<b>Sodium Cromoglycate</b>							
Cap 100 mg	206,229	\$191,607	\$0.9291		C H 1%		
<b>Sodium Phosphate with Phosphoric Acid</b>							
Enema 10% with phosphoric acid 6.58%	49,715	\$124,288	\$2.5000		C H 1%	Note this product is currently listed as 'Sodium Acid Phosphate - Enema 16% with sodium phosphate 8%' in Section B of the Pharmaceutical Schedule	
Oral liq 16.4% with phosphoric acid 25.14%					H 1%		
<b>Sucralfate</b>							
Tab 1 g	116,677	\$34,517	\$0.2958 *		C H 1%		
<b>Sulfasalazine</b>							
Tab 500 mg	254,065	\$35,569	\$0.1400		C H 1%		
Tab EC 500 mg	6,212,978	\$838,752	\$0.1350		C H 1%		
<b>Thymol glycerin</b>							
Compound, BPC	249,385	\$4,564	\$0.0183		C H 1%		
<b>Vitamin B complex (strong)</b>							
Tab	3,362,645	\$48,086	\$0.0143		C H 1%		
<b>Zinc</b>							
Oral liq 5 mg per 5 drops					H 1%		
<b>Zinc chloride</b>							
Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml					H 1%		
<b>Zinc sulphate</b>							
Cap 50 mg elemental	1,115,400	\$122,694	\$0.1100		C H 1%	This product has specific Medsafe requirements that must be met before a tender decision could be made.	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Blood and Blood Forming Organs**

<b>Chemical Name</b>							
Line Item	Units	Cost	Unit Subsidy		DV Limit		Comments
<b>Aspirin</b>							
<u>Tab 75 mg - 100 mg</u>	92,893,156	\$1,173,241	\$0.0126		C H 10%		Units and unit subsidy shown are per 100 mg tablet
<u>Tab dispersible or soluble 300 mg</u>	1,108,683	\$43,239	\$0.0390		C H 1%		
<b>Clopidogrel</b>							
<u>Tab 75 mg</u>	10,428,416	\$675,344	\$0.0648		C H 1%		
<b>Compound electrolytes</b>							
<u>Powder for soln for oral use</u>	1,331,745	\$306,301	\$0.2300		C H 1%		Units and unit subsidy expressed as 'per sachet'. There may be a preference for products to include a measuring device or to come in unit dose sachets. Preference for pack sizes of 10 - 20 sachet packs.
<b>Dipyridamole</b>							
<u>Oral long-acting 150 mg</u>	2,691,607	\$516,789	\$0.1920		C H 1%		
<b>Pegfilgrastim</b>							
Inj 6 mg per 0.6 ml prefilled syringe	6,943	\$7,498,440	\$1,080.0000 #		C H 1%		Special Authority restrictions may apply.
<b>Sodium chloride</b>							
Inj 0.9%, 5 ml	103,697	\$14,518	\$0.1400		C H 1%		There may be a preference for plastic ampoules
<u>Inj 0.9%, 10 ml</u>	505,106	\$66,977	\$0.1326		C H 1%		There may be a preference for plastic ampoules
Inj 0.9%, 20 ml	132,810	\$33,203	\$0.2500		C H 1%		There may be a preference for plastic ampoules
<b>Ticagrelor</b>							
Tab 90 mg	2,729,000	\$4,385,885	\$1.6071	+	C H 1%		Special Authority restrictions may apply.
<b>Tranexamic acid</b>							
<u>Tab 500 mg</u>	2,590,657	\$535,489	\$0.2067		C H 1%		

**Cardiovascular System**

<b>Chemical Name</b>							
Line Item	Units	Cost	Unit Subsidy		DV Limit		Comments
<b>Adenosine</b>							
Inj 3 mg per ml, 10 ml					H 1%		
Inj 3 mg per ml, 2 ml					H 1%		
<b>Ajmaline</b>							
Inj 50 mg per 10 ml					H 1%		
<b>Amiloride with Hydrochlorothiazide</b>							
Tab 5 mg with hydrochlorothiazide 50 mg	801,062	\$80,106	\$0.1000		C H 1%		
<b>Amiodarone hydrochloride</b>							
<u>Inj 50 mg per ml, 3 ml</u>	8,740	\$17,445	\$1.9960		C H 1%		
<u>Tab 100 mg</u>	528,757	\$82,132	\$0.1553		C H 1%		
<u>Tab 200 mg</u>	755,054	\$192,033	\$0.2543		C H 1%		
<b>Candesartan cilexetil with hydrochlorothiazide</b>							
Tab 16 mg with hydrochlorothiazide 12.5 mg					C H 1%		Not currently listed in the Pharmaceutical Schedule.
Tab 32 mg with hydrochlorothiazide 12.5 mg					C H 1%		Not currently listed in the Pharmaceutical Schedule.
Tab 32 mg with hydrochlorothiazide 25 mg					C H 1%		Not currently listed in the Pharmaceutical Schedule.
<b>Captopril</b>							
Oral liq 5 mg per ml	144,685	\$144,669	\$0.9999		C H 1%		
<b>Chlortalidone [Chlorthalidone]</b>							
Tab 25 mg	2,714,678	\$434,348	\$0.1600		C H 1%		
<b>Cilazapril</b>							
Tab 0.5 mg	21,243,017	\$472,020	\$0.0222		C H 1%		Note market data for this product is subject to change.

sole supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Cardiovascular System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
<b>Cilazapril</b>					
<u>Tab 2.5 mg</u>	22,754,620	\$819,166	\$0.0360	C H 1%	Note market data for this product is subject to change.
<u>Tab 5 mg</u>	26,022,040	\$1,561,322	\$0.0600	C H 1%	Note market data for this product is subject to change.
<b>Cilazapril with hydrochlorothiazide</b>					
<u>Tab 5 mg with hydrochlorothiazide 12.5 mg</u>	19,327,789	\$1,967,569	\$0.1018	C H 1%	
<b>Diazoxide</b>					
Inj 15 mg per ml, 20 ml				H 1%	
<b>Digoxin</b>					
Inj 250 mcg per ml, 2 ml				H 1%	
Oral liq 50 mcg per ml	12,626	\$3,493	\$0.2767	C H 1%	
<u>Tab 250 mcg</u>	928,869	\$56,197	\$0.0605	C H 1%	
<u>Tab 62.5 mcg</u>	7,665,371	\$213,021	\$0.0278	C H 1%	
<b>Enalapril</b>					
Tab 5 mg	2,442,856	\$23,451	\$0.0096	C H 1%	Preference for a scored tablet.
Tab 10 mg	2,601,687	\$32,261	\$0.0124	C H 1%	
Tab 20 mg	3,243,209	\$57,729	\$0.0178	C H 1%	
<b>Furosemide</b>					
Inj 10 mg per ml, 25 ml	502	\$4,833	\$9.6283	C H 1%	
<u>Inj 10 mg per ml, 2 ml</u>	10,188	\$2,445	\$0.2400	C H 1%	
<b>Furosemide [Frusemide]</b>					
Oral liq 10 mg per ml	78,900	\$28,036	\$0.3553	C H 1%	
<b>Gemfibrozil</b>					
<u>Tab 600 mg</u>	371,717	\$121,180	\$0.3260	C H 1%	
<b>Glyceryl trinitrate</b>					
Spray 400 mcg per dose	5,259,900	\$93,626	\$0.0178	C H 1%	
Tab 600 mcg	3,700	\$296	\$0.0800	C H 1%	
Patch 25 mg, 5 mg per day	63,942	\$33,527	\$0.5243	C H 1%	
Patch 50 mg, 10 mg per day	29,253	\$18,156	\$0.6207	C H 1%	
<b>Iloprost</b>					
Inj 100 mcg per ml, 0.5 ml				H 1%	
Nebuliser soln 10 mcg per ml, 2 ml	14,308	\$565,166	\$39.5000 #	C H 1%	Special Authority restrictions may apply.
<b>Indapamide</b>					
<u>Tab 2.5 mg</u>	1,408,970	\$40,705	\$0.0289	C H 1%	
<b>Levosimendan</b>					
Inj 2.5 mg per ml, 10 ml				H 1%	
Inj 2.5 mg per ml, 5 ml				H 1%	
<b>Mexiletine</b>					
Cap 150 mg	41,739	\$67,617	\$1.6200	C H 1%	
Cap 250 mg	10,529	\$21,269	\$2.0200	C H 1%	
<b>Nicorandil</b>					
Tab 10 mg	508,113	\$236,694	\$0.4658 #	C H 1%	
Tab 20 mg	103,701	\$57,520	\$0.5547 #	C H 1%	
<b>Nimodipine</b>					
Inj 0.2 mg per ml, 50 ml				H 1%	
Tab 30 mg				H 1%	
<b>Noradrenaline</b>					
Inj 0.06 mg per ml, 100 ml bag				H 1%	
Inj 0.06 mg per ml, 50 ml syringe				H 1%	
Inj 0.1 mg per ml, 100 ml bag				H 1%	
Inj 0.12 mg per ml, 100 ml bag				H 1%	
Inj 0.12 mg per ml, 50 ml syringe				H 1%	
Inj 0.16 mg per ml, 50 ml syringe				H 1%	

sole supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Cardiovascular System**

<b>Chemical Name</b>					<b>DV</b>	
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>Limit</b>	<b>Comments</b>
<b>Noradrenaline</b>						
Inj 1 mg per ml, 100 ml bag					H 1%	
Inj 1 mg per ml, 4 ml ampoule					H 1%	
<b>Perhexiline maleate</b>						
<u>Tab 100 mg</u>	267,095	\$168,002	\$0.6290		C H 1%	
<b>Phentolamine Mesylate</b>						
Inj 10 mg per ml, 1 ml					H 1%	
Inj 5 mg per ml, 1 ml					H 1%	
<b>Propranolol</b>						
Cap long-acting 160 mg	539,825	\$98,086	\$0.1817		C H 1%	
Oral liq 4 mg per ml	207,345				C H 1%	This is currently a Cost Brand Source product. Units are expressed as 'per ml'
Inj 1 mg per ml, 1 ml					H 1%	
<b>Sildenafil</b>						
Inj 0.8 mg per ml, 12.5 ml vial					H 1%	
<b>Sodium nitroprusside</b>						
Inj 50 mg					H 1%	
<b>Sotalol</b>						
<u>Tab 80 mg</u>	3,430,152	\$271,188	\$0.0791		C H 1%	
<u>Tab 160 mg</u>	165,915	\$20,706	\$0.1248		C H 1%	
<b>Spirolactone</b>						
Oral liq 5 mg per ml	31,550	\$37,860	\$1.2000		C H 1%	
<u>Tab 25 mg</u>	6,628,265	\$290,318	\$0.0438		C H 1%	Tender is for tablets only, bids for capsules will not be accepted
<u>Tab 100 mg</u>	1,338,591	\$157,954	\$0.1180		C H 1%	Tender is for tablets only, bids for capsules will not be accepted
<b>Terazosin hydrochloride</b>						
<u>Tab 1 mg</u>	794,319	\$16,736	\$0.0211		C H 1%	
<u>Tab 2 mg</u>	4,127,672	\$61,915	\$0.0150		C H 1%	
<u>Tab 5 mg</u>	2,999,771	\$65,395	\$0.0218		C H 1%	

**Dermatologicals**

<b>Chemical Name</b>					<b>DV</b>	
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>Limit</b>	<b>Comments</b>
<b>Adapalene</b>						
Crn 0.1%	253,140	\$193,146	\$0.7630 #		C H 1%	Preference for a maximum pack size of 30 g
Gel 0.1%	439,650	\$335,453	\$0.7630 #		C H 1%	Preference for a maximum pack size of 30 g
<b>Betamethasone Dipropionate</b>						
Crn 0.05% (pack size 30 g and over)	183,900				C H	
Crn 0.05% (pack size 30 g and under)					H 1%	
Oint 0.05% (pack size 30 g and over)	224,155				C H	
Oint 0.05% (pack size 30 g and under)					H 1%	
<b>Calcium Gluconate</b>						
Gel 2.5%					H 1%	Preference for a pack size of 40 g - 100 g
<b>Cetomacrogol with glycerol</b>						
<u>Crn 90% with glycerol 10%, 1,000 ml</u>	67,048,890	\$259,479	\$0.0039		C H 1%	There may be a preference for a sodium lauryl sulphate (SLS)-free presentation. There may be a preference for a pump bottle
Crn 90% with glycerol 10%, 100 g					H 1%	There may be a preference for a sodium lauryl sulphate (SLS)-free presentation. There may be a preference for a tube

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Dermatologicals**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Cetomacrogol with glycerol</b>						
<u>Crn 90% with glycerol 10%, 500 ml</u>	109,395,558	\$616,991	\$0.0056		C H 1%	There may be a preference for a sodium lauryl sulphate (SLS)-free presentation. There may be a preference for a pump bottle
<b>Clobetasol propionate</b>						
<u>Crn 0.05% (pack size 30 g or less)</u>	3,722,250	\$272,953	\$0.0733		C H 1%	
<u>Oint 0.05% (pack size 30 g or less)</u>	3,484,800	\$255,540	\$0.0733		C H 1%	
Scalp app 0.05%	690,240	\$160,136	\$0.2320		C H 1%	
<b>Clobetasone butyrate</b>						
Crn 0.05% (pack size 30 g or less)	423,870	\$76,013	\$0.1793		C H 1%	
<b>Diflucortolone Valerate</b>						
Crn 0.1%	107,600	\$19,303	\$0.1794 *		C H 1%	
Fatty oint 0.1%	149,400	\$26,802	\$0.1794 *		C H 1%	
<b>Dimethicone</b>						
Lotn 4% - head lice suffocant	3,584,800	\$89,262	\$0.0249		C H 1%	
<u>Crn 5% (pack size greater than 100 g)</u>	1,856,500	\$17,043	\$0.0092		C 1%	There may be a preference for a pump bottle
<b>Hydrocortisone</b>						
<u>Crn 1% (pack size greater than 15 g and less than or equal to 100 g)</u>	17,104,366	\$632,862	\$0.0370		C H 1%	There may be a preference for a sodium lauryl sulphate (SLS)-free presentation. Subsidies shown are for 30 g presentation.
<u>Crn 1% (pack size greater than 100 g)</u>	17,104,366	\$555,892	\$0.0325		C H 1%	There may be a preference for a sodium lauryl sulphate (SLS)-free presentation
<b>Methylprednisolone aceponate</b>						
Crn 0.1%	592,350	\$195,476	\$0.3300		C H 1%	
Oint 0.1%	359,175	\$118,528	\$0.3300		C H 1%	
<b>Mupirocin (pack size 5 g or less)</b>						
Oint 2%	626,565	\$275,689	\$0.4400 *		C H 1%	Any agreement may be subject to Special Authority restriction. Intended for intra-nasal administration only. All other pack sizes of mupirocin would be delisted should a tender award be made.
<b>Nystatin</b>						
Crn 100,000 u per g	15,990	\$1,066	\$0.0667 *		C H 1%	
<b>Paraffin</b>						
White soft - 2,500 g	2,253,779	\$18,211	\$0.0081		C	PHARMAC reserves the right to amend access.
White soft - 500 g	2,253,779	\$16,137	\$0.0072 *		C H 1%	PHARMAC reserves the right to amend access.
<b>Phenothrin</b>						
Shampoo 0.5%	5,682,900	\$322,789	\$0.0568 #		C H 1%	
<b>Podophyllotoxin</b>						
Soln 0.5%	10,420	\$100,027	\$9.6000		C H 1%	
<b>Povidone Iodine</b>						
Skin preparation, povidone iodine 10% with 30% alcohol (pack size 100 ml or less)	74,325	\$1,211	\$0.0163 *		C H 1%	
Skin preparation, povidone iodine 10% with 30% alcohol (pack size greater than 100 ml)	74,325	\$1,487	\$0.0200		C H 1%	
<b>Salicylic Acid</b>						
Powder	239,985	\$18,124	\$0.0755		C H 1%	
<b>Sulphur</b>						
Precipitated	4,646	\$295	\$0.0635		C H 1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Dermatologicals**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
<b>Sunscreens, proprietary</b>						
SPF 50+ or greater	740,100	\$24,423	\$0.0330	C H	1%	Subsidy by endorsement only. Please note there are two formulations currently listed in the Pharmaceutical Schedule, tender award would result in one formulation being delisted. Unit and subsidy data reflect sunscreen lotion market.
<b>Triclosan</b>						
Soln 1%	1,991,000	\$23,494	\$0.0118	C		Preference for pack size of 500 ml or less. Subsidy by endorsement only.
<b>Urea</b>						
<u>Crn 10%</u>	19,018,800	\$260,558	\$0.0137	C H	1%	Preference for 10 g pack size. There may be a preference for a tube.

**Extemporaneously Compounded Preparations**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
<b>Coal tar</b>						
<u>Soln BP</u>	181,902	\$29,968	\$0.1648	C H	1%	There may be a preference for a pack size of 100 ml or less
<b>Compound Hydroxybenzoate</b>						
Soln	44,308	\$14,219	\$0.3209	C H	1%	Units expressed as per 'ml'. More than one brand is currently listed in the Pharmaceutical Schedule. Unit subsidy shown as the average unit subsidy of the products listed in the 2018 FYR.
<b>Glycerin with sodium saccharin</b>						
Suspension	84,948	\$5,837	\$0.0687	C H	1%	
<b>Glycerin with sucrose</b>						
Suspension	469,226	\$32,241	\$0.0687	C H	1%	
<b>Methyl Hydroxybenzoate</b>						
Powder	2,143	\$770	\$0.3592	C H	1%	
<b>Methylcellulose</b>						
Powder	2,628	\$971	\$0.3695	C H	1%	
Suspension	617,816	\$42,450	\$0.0687	C H	1%	
<b>Methylcellulose with glycerin and sodium saccharin</b>						
Suspension	865,831	\$59,491	\$0.0687	C H	1%	
<b>Methylcellulose with glycerin and sucrose</b>						
Suspension	1,260,226	\$86,590	\$0.0687	C H	1%	
<b>Sodium Bicarbonate</b>						
Powder BP	339,633	\$6,079	\$0.0179 *	C H	1%	
<b>Sodium citrate</b>						
Powder				H	1%	
<b>Syrup (pharmaceutical grade)</b>						
Liq	149,675	\$1,628	\$0.0109	C H	1%	
<b>Zinc oxide</b>						
Powder				H	1%	

**Genito Urinary System**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
<b>Carboprost</b>						
Inj 250 mcg per ml, 1ml					H 1%	
<b>Clotrimazole</b>						
<u>Vaginal crm 1% with applicators</u>	1,772,015	\$80,999	\$0.0457	C H	1%	
<u>Vaginal crm 2% with applicators</u>	1,566,960	\$164,531	\$0.1050	C H	1%	

sole supply

#=rebate \*=part charge @=ASP +=patent



**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Genito Urinary System**

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
<b>Ethinylloestradiol with Desogestrel</b>					
Tab 20 mcg with desogestrel 150 mcg	295,708	\$23,305	\$0.0788 *	C H 1%	
Tab 30 mcg with desogestrel 150 mcg	294,252	\$23,190	\$0.0788 *	C H 1%	
<b>Ethinylloestradiol with Norethisterone</b>					
Tab 35 mcg with norethisterone 1 mg	100,296	\$10,539	\$0.1051	C H 1%	
Tab 35 mcg with norethisterone 500 mcg	100,149	\$10,524	\$0.1051	C H 1%	
<b>Intra-Uterine Copper Device</b>					
IUD long	4,577	\$144,633	\$31.6000	C H 1%	PHARMAC reserves the right to award one, some or all presentations of intra-uterine copper device. Refer to Schedule 7 for additional Special Terms.
IUD medium	6,363	\$201,071	\$31.6000	C H 1%	PHARMAC reserves the right to award one, some or all presentations of intra-uterine copper device. Refer to Schedule 7 for additional Special Terms.
IUD short	3,038	\$96,001	\$31.6000	C H 1%	PHARMAC reserves the right to award one, some or all presentations of intra-uterine copper device. Refer to Schedule 7 for additional Special Terms.
<b>Levonorgestrel</b>					
1.5 mg	70,593	\$349,435	\$4.9500	C H 1%	
Tab 30 mcg	196,644	\$15,498	\$0.0788# *	C H	
<b>Medroxyprogesterone acetate</b>					
<u>Inj long-acting 150 mg per ml, 1 ml syringe</u>	145,778	\$1,056,891	\$7.2500	C H 1%	
<b>Mifepristone</b>					
Tab 200 mg				H 1%	
<b>Oxybutynin</b>					
<u>Oral liq 1 mg per ml</u>	392,786	\$50,159	\$0.1277	C H 1%	
<u>Tab 5 mg</u>	6,053,064	\$107,139	\$0.0177	C H 1%	
<b>Tamsulosin [Current Access]</b>					
<u>Tab 400 mcg</u>	2,230,859	\$250,972	\$0.1125	C H 1%	Special Authority restrictions may apply. PHARMAC would only award a tender for either current or widened access.
<b>Tamsulosin [Widened Access]</b>					
Tab 400 mcg					PHARMAC would only award a tender for either current or widened access. Widened access would result in removal of Special Authority criteria.
<b>Tolteridone tartrate</b>					
Tab 1 mg	150,661	\$39,172	\$0.2600	C H 1%	Special Authority restrictions may apply.
Tab 2 mg	167,115	\$43,450	\$0.2600	C H 1%	Special Authority restrictions may apply.

**Hormone Preparations - Systemic Excluding Contraceptive Hormones**

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
<b>Betamethasone</b>					
Inj 4 mg per ml, 1 ml				H 1%	
Tab 400 mg				H 1%	
<b>Betamethasone Sodium Phosphate with Betamethasone Acetate</b>					
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1ml	883	\$3,391	\$3.8400	C H 1%	
<b>Calcitonin</b>					
Inj 100 iu per ml, 1 ml	567	\$13,721	\$24.2000	C H 1%	
<b>Desmopressin</b>					
Inj 15 mcg per ml, 1 ml				H 1%	
Inj 4 mcg per ml, 1 ml	4,925	\$33,086	\$6.7180	C H 1%	
Nasal drops 100 mcg per ml	5,443	\$84,968	\$15.6120	C H 1%	
<u>Tab 100 mcg</u>	75,658	\$63,048	\$0.8333	C H 1%	Special Authority restrictions may apply

sole supply

#=rebate \*=part charge @=ASP +=patent

## SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

### Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
<b>Desmopressin</b>						
Tab 200 mcg	34,137	\$61,959	\$1.8150		C H 1%	Special Authority restrictions may apply
<b>Dexamethasone phosphate</b>						
Inj 4 mg per ml, 1 ml	54,092	\$76,757	\$1.4190		C H 1%	
Inj 4 mg per ml, 2 ml	87,513	\$220,359	\$2.5180		C H 1%	
<b>Hydrocortisone</b>						
Inj 50 mg per ml, 2 ml	5,558	\$29,457	\$5.3000		C H 1%	
<b>Medroxyprogesterone acetate</b>						
Tab 2.5 mg	565,728	\$70,716	\$0.1250		C H 1%	
Tab 5 mg	697,383	\$97,634	\$0.1400		C H 1%	
Tab 10 mg	1,469,736	\$350,282	\$0.2383		C H 1%	
Tab 100 mg	30,276	\$30,579	\$1.0100		C H 1%	
<b>Methylprednisolone Acetate with Lignocaine</b>						
Inj 40 mg per ml with lignocaine 1 ml	1,877	\$17,362	\$9.2500		C H 1%	
Inj 40 mg per ml with lignocaine 2 ml					C H 1%	Not currently listed on the Pharmaceutical Schedule.
<b>Oestradiol</b>						
Tab 1 mg	376,432	\$55,388	\$0.1471	*	C H 1%	
Tab 2 mg	240,492	\$35,386	\$0.1471	*	C H 1%	
TDDS 25 mcg per day	184,669	\$141,272	\$0.7650		C H 1%	
TDDS 50 mcg per day	236,200	\$207,856	\$0.8800		C H 1%	
TDDS 75 mcg per day	29,116	\$28,788	\$0.9888		C H 1%	
TDDS 100 mcg per day	82,208	\$81,283	\$0.9888		C H 1%	
<b>Progesterone</b>						
Cap 100 mg	36,283	\$19,956	\$0.5500		C H 1%	PHARMAC reserves the right to amend access. Must be compatible for intra-vaginal use. Special Authority restrictions may apply.
<b>Tetracosactide [Tetracosactrin]</b>						
Inj 250 mcg per ml, 1 ml	338	\$25,350	\$75.0000		C H 1%	
Inj 1 mg per ml, 1 ml	17	\$11,730	\$690.0000		C H 1%	

### Infections

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
<b>Aciclovir</b>						
Tab dispersible 200 mg	792,396	\$50,713	\$0.0640		C H 1%	
Tab dispersible 400 mg	5,413,657	\$520,090	\$0.0961		C H 1%	
Tab dispersible 800 mg	781,363	\$133,504	\$0.1709		C H 1%	
<b>Albendazole</b>						
Tab	1,606	\$12,559	\$7.8200		C H 1%	Special Authority restrictions may apply. Note units and unit subsidy corresponds to the currently listed tab 400 mg presentation. All strengths received as tender bids will be reviewed.
<b>Amoxicillin</b>						
Cap 250 mg	911,690	\$27,296	\$0.0299		C H 1%	
Cap 500 mg	16,473,632	\$551,867	\$0.0335		C H 1%	
<b>Amoxicillin clavulanate</b>						
Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml	3,878,853	\$148,560	\$0.0383	@	C H 1%	PHARMAC reserves the right to award one or more strengths of amoxicillin with clavulanic acid oral liquids. Additional Stock Pharmaceutical. There may be a preference for a 100 ml packsize
Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml	9,946,000	\$218,812	\$0.0220	@	C H 1%	PHARMAC reserves the right to award one or more strengths of amoxicillin with clavulanic acid oral liquids. Additional Stock Pharmaceutical. There may be a preference for a 100 ml packsize

sole supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Infections**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
Line Item					
<b>Amoxicillin clavulanate</b>					
Inj 500 mg with clavulanic acid 100 mg				H 1%	
Inj 1000 mg with clavulanic acid 200 mg				H 1%	
<b>Amphotericin B</b>					
Liposomal inj 50 mg				H 1%	Bids for liposomal formulations will be evaluated only.
<b>Caspofungin</b>					
Inj 50 mg				H 1%	
Inj 70 mg				H 1%	
<b>Cefaclor monohydrate</b>					
<u>Cap 250 mg</u>	2,905,825	\$717,739	\$0.2470	C H 1%	
<u>Grans for oral liq 125 mg per 5 ml</u>	5,035,144	\$177,741	\$0.0353	C H 1%	
<b>Cefalexin monohydrate</b>					
Cap 250 mg	190,888	\$33,405	\$0.1750	C H 1%	Not currently listed in the Pharmaceutical Schedule
<u>Cap 500 mg</u>	2,219,661	\$438,383	\$0.1975	C H 1%	
<b>Cefotaxime</b>					
Inj 500 mg				H 1%	
<b>Cefoxitin Sodium</b>					
Inj 1 g				H 1%	
<b>Ceftriaxone sodium</b>					
<u>Inj 500 mg</u>	5,646	\$6,775	\$1.2000	C H 1%	
<u>Inj 1 g</u>	5,501	\$4,621	\$0.8400	C H 1%	
Inj 2 g				H 1%	
<b>Cefuroxime Axetil</b>					
Tab 250 mg	10,176	\$5,983	\$0.5880	C H 1%	
<b>Clarithromycin</b>					
Grans for oral liq 250 mg per 5 ml	4,009	\$1,854	\$0.4624	C H 1%	
<b>Clindamycin</b>					
<u>Cap hydrochloride 150 mg</u>	686,316	\$175,869	\$0.2563	C H 1%	
<u>Inj 150 mg per ml, 4 ml</u>	193	\$1,255	\$6.5000	C H 1%	
<b>Dapsone</b>					
Tab 100 mg	35,877	\$118,213	\$3.2950	C H 1%	
Tab 25 mg	83,714	\$224,772	\$2.6850	C H 1%	
<b>Doxycycline</b>					
Inj 100 mg per 20 ml				H 1%	
Tab 100 mg	9,555,517	\$257,999	\$0.0270	C H 1%	
Tab 50 mg	637,398	\$61,617	\$0.0967 *	C H 1%	
<b>Ertapenem</b>					
Inj 1 g vial				H 1%	
<b>Erythromycin Ethyl Succinate</b>					
Grans for oral liq 200 mg per 5 ml	3,243,230	\$162,162	\$0.0500	C H 1%	
Grans for oral liq 400 mg per 5 ml	3,692,468	\$249,980	\$0.0677	C H 1%	
Tab 400 mg	3,351,051	\$568,003	\$0.1695	C H 1%	
<b>Erythromycin Lactobionate</b>					
Inj 1 g	419	\$6,704	\$16.0000	C H 1%	
<b>Erythromycin Stearate</b>					
Tab 250 mg	105,303	\$15,743	\$0.1495 *	C H 1%	
Tab 500 mg	48,180	\$14,406	\$0.2990 *	C H 1%	
<b>Ethambutol hydrochloride</b>					
Tab 100 mg	30,123	\$25,825	\$0.8573	C H 1%	
Tab 400 mg	80,351	\$70,809	\$0.8813	C H 1%	
<b>Fluconazole</b>					
<u>Inj 2 mg per ml, 50 ml</u>				H 1%	
<u>sole supply</u>					

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Infections**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
Line Item					
<b>Fluconazole</b>					
Inj 2 mg per ml, 100 ml				H 1%	
<b>Ganciclovir</b>					
Inj 500 mg				H 1%	
<b>Hexamine hippurate</b>					
Tab 1 g	451,231	\$83,027	\$0.1840 *	C H 1%	
<b>Itraconazole</b>					
Cap 100 mg	306,370	\$56,985	\$0.1860	C H 1%	
<b>Ketoconazole</b>					
Tab 200 mg	1,938			C H 1%	This is a cost-brand source product.
<b>Lincomycin</b>					
Inj 300 mg per ml, 2 ml				H 1%	
<b>Metronidazole</b>					
Inj 5 mg per ml, 100 ml bag				H 1%	
Inj 5 mg per ml, 100 ml bottle				H 1%	
<b>Minocycline hydrochloride</b>					
Cap 100 mg	134,993		*	C H 1%	PHARMAC may choose to accept one or both presentations of minocycline capsules or tablets.
Tab 50 mg	510,539		*	C H 1%	PHARMAC may choose to accept one or both presentations of minocycline capsules or tablets. Special Authority restrictions may apply.
<b>Moxifloxacin</b>					
Inj 1.6 mg per ml, 250 ml				H 1%	
Tab 400 mg	11,564	\$120,266	\$10.4000	C H 1%	May be subject to Special Authority restrictions.
<b>Nitazoxanide</b>					
Tab 500 mg				H 1%	
<b>Nitrofurantoin</b>					
Modified-release 100 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule.
<b>Norfloxacin</b>					
Tab 400 mg	129,898	\$175,362	\$1.3500	C H 1%	
<b>Nystatin</b>					
Cap 500,000 u	100,731	\$25,807	\$0.2562 *	C H 1%	
Tab 500,000 u	39,572	\$11,207	\$0.2832 *	C H 1%	
<b>Ornidazole</b>					
Tab 500 mg	134,247	\$308,768	\$2.3000	C H 1%	
<b>Paromomycin</b>					
Cap 250 mg	951	\$7,489	\$7.8750	C H 1%	Special Authority restrictions may apply.
<b>Pentamidine isethionate</b>					
Inj 300 mg				H 1%	
<b>Phenoxymethylpenicillin (Penicillin V)</b>					
Cap 250 mg	301,981	\$15,643	\$0.0518	C H 1%	
Cap 500 mg	1,939,886	\$165,278	\$0.0852	C H 1%	
Grans for oral liq 125 mg per 5 ml	522,052	\$7,726	\$0.0148	C H 1%	
Grans for oral liq 250 mg per 5 ml	3,680,663	\$58,154	\$0.0158	C H 1%	
<b>Piperacillin with tazobactam</b>					
Inj 4 g with tazobactam 500 mg				H 1%	
<b>Pivmecillinam</b>					
Tab 200 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions.

sole supply

#=rebate \*=part charge @=ASP +=patent

## SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

### Infections

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Posaconazole</b>					
Oral liq 40 mg per ml	10,290	\$74,591	\$7.2489 #	C H 1%	Special Authority restrictions may apply.
Tab modified-release 100 mg	25,941	\$940,210	\$36.2442 #	C H 1%	Special Authority restrictions may apply.
<b>Protionamide</b>					
Tab 250 mg	6,380	\$19,459	\$3.0500	C H 1%	
<b>Rifabutin</b>					
Cap 150 mg	3,545	\$32,496	\$9.1667	C H 1%	
<b>Roxithromycin</b>					
Dispersible tab - 50 mg	14,826	\$10,660	\$0.7190	C H 1%	
Tab 150 mg	2,101,510	\$314,386	\$0.1496 @	C H 1%	Additional Stock Pharmaceutical
Tab 300 mg	908,287	\$261,587	\$0.2880 @	C H 1%	Additional Stock Pharmaceutical
<b>Spiramycin</b>					
Tab 500 mg				H 1%	
<b>Tetracycline</b>					
Cap 500 mg	21,174	\$32,467	\$1.5333	C H 1%	Special Authority restrictions may apply.
Tab 250 mg				H 1%	
<b>Tigecycline</b>					
Inj 50 mg				H 1%	
<b>Trimethoprim with sulphamethoxazole [Co-trimoxazole]</b>					
Tab trimethoprim 80 mg and sulphamethoxazole 400 mg	3,577,008	\$163,827	\$0.0458	C H 1%	
<b>Voriconazole</b>					
Inj 200 mg				H 1%	
<b>Zidovudine [AZT]</b>					
Cap 100 mg	3,200	\$4,872	\$1.5225	C H 1%	Special Authority restrictions may apply.
Oral liq 10 mg per ml	1,200	\$183	\$0.1523	C H 1%	Special Authority restrictions may apply.
Inj 10 mg per ml, 20 ml vial				H 1%	

### Musculoskeletal System

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Capsaicin</b>					
Crm 0.025%	1,118,655	\$247,335	\$0.2211 #	C H 1%	Subsidy shown is for the 45 g pack size.
<b>Diclofenac sodium</b>					
Tab 50 mg dispersible	868,806	\$65,160	\$0.0750	C H 1%	
<b>Edrophonium chloride</b>					
Inj 10 mg per ml, 1 ml				H 1%	
Inj 10 mg per ml, 15 ml				H 1%	
<b>Hyaluronidase</b>					
Inj 1,500 iu per ml				H 1%	
<b>Ketoprofen</b>					
Cap long-acting 200 mg	98,669	\$42,533	\$0.4311	C H 1%	
<b>Meloxicam [current access]</b>					
Tab 7.5 mg	19,406	\$7,439	\$0.3833	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. Note 'current access' refers to access available as of 1 July 2018
<b>Meloxicam [widened access]</b>					
Tab 7.5 mg				C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. Widened access would result in open access (e.g. no restrictions).

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Musculoskeletal System**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
<b>Pyridostigmine bromide</b>						
Tab 60 mg	492,013	\$210,532	\$0.4279	C H	1%	
<b>Rasburicase</b>						
Inj 1.5 mg				H	1%	
<b>Risedronate sodium</b>						
Tab 35 mg	302,048	\$286,946	\$0.9500	C H	1%	
<b>Rocuronium bromide</b>						
Inj 10 mg per ml, 5 ml				H	1%	
<b>Tenoxicam</b>						
Inj 20 mg			\$9.9500	C H	1%	
Tab 20 mg	694,866	\$76,088	\$0.1095	C H	1%	
<b>Teriparatide</b>						
Inj 250 mcg per ml, 2.4 ml	2,252	\$1,103,480	\$490.0000#	C H	1%	Special Authority restrictions may apply.
<b>Vecuronium</b>						
Inj 10 mg				H	1%	
<b>Zoledronic Acid</b>						
Inj 0.05 mg per ml, 100 ml	1,132,700	\$6,796,200	\$6.0000#	C H	1%	Special Authority restrictions may apply.

**Nervous System**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
<b>Amisulpride</b>						
Oral liq 100 mg per ml	16,346	\$17,852	\$1.0922	C H	1%	
Tab 100 mg	321,530	\$48,873	\$0.1520	C H	1%	
Tab 200 mg	333,279	\$81,930	\$0.2458	C H	1%	
Tab 400 mg	118,929	\$54,906	\$0.4617	C H	1%	
<b>Articaine hydrochloride</b>						
Inj 1%				H	1%	
<b>Articaine hydrochloride with adrenaline</b>						
Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge				H	1%	
Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge				H	1%	
Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge				H	1%	
Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge				H	1%	
<b>Benzatropine Mesylate</b>						
Inj 1 mg per ml, 2 ml	1,809	\$34,371	\$19.0000	C H	1%	
Tab 2 mg	777,238	\$103,505	\$0.1332	C H	1%	
<b>Benzocaine</b>						
Gel 20%				H	1%	
<b>Bupivacaine hydrochloride</b>						
Inj 2.5 mg per ml, 20 ml ampoule				H	1%	
Inj 5 mg per ml, 20 ml ampoule				H	1%	
Inj 1.25 mg per ml, 100 ml bag				H	1%	
Inj 1.25 mg per ml, 200 ml bag				H	1%	
Inj 1.25 mg per ml, 500ml bag				H	1%	
Inj 2.5 mg per ml, 200 ml bag				H	1%	
<b>Bupivacaine hydrochloride with adrenaline</b>						
Inj 0.25% with 1:400,000 of adrenaline, 20 ml non-sterile pack				H	1%	
Inj 0.5% with 1:200,000 of adrenaline, 20 ml non-sterile pack				H	1%	

## SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

### Nervous System

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
<b>Bupivacaine hydrochloride with fentanyl</b>						
Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag					H 1%	
Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag					H 1%	
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe					H 1%	
Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe					H 1%	
Inj 1.25mg with 2 mcg fentanyl per ml, 15 ml syringe					H 1%	Sterile pack preferred
Inj 1.25mg with 2 mcg fentanyl per ml, 20 ml syringe					H 1%	
Inj 1.25mg with 2 mcg fentanyl per ml, 100 ml bag					H 1%	
Inj 1.25mg with 2 mcg fentanyl per ml, 200 ml bag					H 1%	
<b>Bupivacaine hydrochloride with glucose</b>						
Inj 0.5% with glucose 8%, 4 ml ampoule					H 1%	Sterile pack preferred
<b>Capsaicin</b>						
Crm 0.075%	305,685	\$84,913	\$0.2778		C H 1%	
<b>Chlorpromazine Hydrochloride</b>						
Inj 25 mg per ml, 2 ml	1,905	\$4,888	\$2.5660		C H 1%	
Oral liq 100 mg per 5 ml					H 1%	
Tab 10 mg	103,539	\$12,797	\$0.1236		C H 1%	
Tab 100 mg	187,065	\$57,261	\$0.3061		C H 1%	
Tab 25 mg	498,585	\$64,916	\$0.1302		C H 1%	
<b>Codeine phosphate</b>						
<u>Tab 15 mg</u>	9,496,525	\$546,050	\$0.0575		C H 1%	
<u>Tab 30 mg</u>	23,879,804	\$1,623,827	\$0.0680		C H 1%	
<u>Tab 60 mg</u>	1,868,972	\$252,311	\$0.1350		C H 1%	
<b>Cyclizine lactate</b>						
Inj 50 mg per ml, 1 ml	60,265	\$180,191	\$2.9900		C H 1%	
<b>Dihydrocodeine tartrate</b>						
<u>Tab long-acting 60 mg</u>	4,763,652	\$758,230	\$0.1592		C H 1%	
<b>Disulfiram</b>						
Tab 200 mg	364,705	\$161,564	\$0.4430		C H 1%	
<b>Dosulepin [Dothiepin] Hydrochloride</b>						
Cap 25 mg	2,500,145	\$161,259	\$0.0645		C H	
Tab 75 mg	904,757	\$101,242	\$0.1119		C H	
<b>Doxepin hydrochloride</b>						
Cap 10 mg	1,160,356	\$73,102	\$0.0630		C H 1%	
Cap 25 mg	1,364,066	\$93,575	\$0.0686		C H 1%	
Cap 50 mg	661,055	\$56,520	\$0.0855		C H 1%	
<b>Droperidol</b>						
Inj 2.5 mg per ml, 1 ml					H 1%	
<b>Fentanyl</b>						
inj 10 mcg per ml, 10 ml syringe					H 1%	
inj 10 mcg per ml, 100 ml premixed bag					H 1%	
inj 10 mcg per ml, 50 ml prefilled syringe					H 1%	
inj 10 mcg per ml, 50 ml premixed bag					H 1%	
inj 20 mcg per ml, 100 ml bag					H 1%	
<b>Fluoxetine hydrochloride [split market]</b>						
<u>Cap 20 mg</u>	21,929,804	\$484,868	\$0.0221		C H 1%	PHARMAC reserves the right to award a tender for capsules for the whole market or two separate tenders for capsules and dispersible tablets

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
<b>Fluoxetine hydrochloride [split market]</b>					
<u>Tab dispersible 20 mg, scored</u>	1,276,860	\$105,124	\$0.0823	C H 1%	PHARMAC reserves the right to award a tender for dispersible tablets for the whole market or two separate tenders for capsules and dispersible tablets
<b>Haloperidol</b>					
<u>Inj 5 mg per ml, 1 ml</u>	85,655	\$184,587	\$2.1550	C H 1%	
<u>Oral liq 2 mg per ml</u>	63,832	\$15,218	\$0.2384	C H 1%	
<u>Tab 500 mcg</u>	1,170,972	\$72,952	\$0.0623	C H 1%	
<u>Tab 1.5 mg</u>	195,233	\$18,410	\$0.0943	C H 1%	
<u>Tab 5 mg</u>	202,784	\$60,267	\$0.2972	C H 1%	
<b>Haloperidol decanoate</b>					
Inj 100 mg per ml, 1 ml ampoule	5,400	\$60,372	\$11.1800	C H 1%	
Inj 50 mg per ml, 1 ml ampoule	3,069	\$17,426	\$5.6780	C H 1%	
<b>Hyoscine (Scopolamine)</b>					
Patches, 1.5 mg	28,861	\$172,444	\$5.9750	C H 1%	Special Authority restrictions may apply.
<b>Hyoscine hydrobromide</b>					
Inj 400 mcg per ml, 1 ml	11,940	\$111,042	\$9.3000	C H 1%	
<b>Imipramine Hydrochloride</b>					
Tab 10 mg	1,106,025	\$121,331	\$0.1097	C H 1%	
Tab 25 mg	314,677	\$55,383	\$0.1760	C H 1%	
<b>Ketamine</b>					
Inj 1 mg per ml, 100 ml bag				H 1%	
Inj 10 mg per ml, 10 ml syringe				H 1%	
Inj 4 mg per ml, 50 ml syringe				H 1%	
<b>Lacosamide</b>					
Inj 10 mg per ml, 20 ml				H 1%	Special Authority restrictions may apply.
<b>Levetiracetam</b>					
<u>Inj 100 mg per ml, 5 ml</u>				H 1%	
Tab 1 g	154,936	\$152,663	\$0.9853 #	C H 1%	
Tab 250 mg	1,560,271	\$624,889	\$0.4005 #	C H 1%	Longer transition periods may apply to this product
Tab 500 mg	4,722,766	\$2,259,843	\$0.4785 #	C H 1%	Longer transition periods may apply to this product
Tab 750 mg	574,978	\$433,436	\$0.7538 #	C H 1%	Longer transition periods may apply to this product
<b>Levomepromazine</b>					
<u>Inj 25 mg per ml, 1 ml</u>	66,327	\$317,640	\$4.7890	C H 1%	
Tab 100 mg	84,057	\$36,951	\$0.4396	C H 1%	Preference for a scored tablet.
Tab 25 mg	482,616	\$81,707	\$0.1693	C H 1%	Preference for a scored tablet.
<b>Lidocaine [Lignocaine]</b>					
Gel 2 %, 10 ml urethral syringe	58,265	\$423,878	\$7.2750	C H 1%	More than one brand is currently listed in the Pharmaceutical Schedule. Unit subsidy shown as the average unit subsidy of the products listed in the 2018 FYR.
<b>Lidocaine [Lignocaine] hydrochloride</b>					
Inj 1%, 20 ml, sterile pack				H 1%	
Inj 2%, 20 ml, sterile pack				H 1%	
Inj 2%, 5 ml, sterile pack				H 1%	Not currently listed in the Pharmaceutical Schedule
Inj, 1%, 5 ml, sterile pack				H 1%	Not currently listed in the Pharmaceutical Schedule
Spray - 10 mg dose per spray				H 1%	
Inj 1%, 5 ml	109,777	\$38,422	\$0.3500	C H 1%	There may be a preference for plastic ampoules.
Inj 1%, 20 ml	2,212	\$5,309	\$2.4000	C H 1%	There may be a preference for plastic ampoules.

sole supply

#=rebate \*=part charge @=ASP +=patent



**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
<b>Lidocaine [Lignocaine] hydrochloride</b>					
Inj 2%, 5 ml	23,062	\$6,365	\$0.2760	C H 1%	There may be a preference for plastic ampoules.
Inj 2%, 20 ml	285	\$684	\$2.4000	C H 1%	There may be a preference for plastic ampoules.
<b>Lidocaine [lignocaine] hydrochloride with adrenaline</b>					
Inj 1% with adrenaline 1:100,000, 5 ml				H 1%	
Inj 1% with adrenaline 1:200,000, 20 ml				H 1%	Sterile pack preferred
Inj 2% with adrenaline 1:200,000, 20 ml				H 1%	Sterile pack preferred
<b>Lidocaine [Ligocaine] hydrochloride with chlorhexidine</b>					
Gel 2% with 0.05% chlorhexidine, 10 ml urethral syringe				H 1%	
<b>Lithium carbonate (immediate-release)</b>					
Cap 250 mg	1,763,507	\$166,122	\$0.0942	C H 1%	
Tab 250 mg	1,484,999	\$101,871	\$0.0686	C H 1%	
Tab 400 mg	321,391	\$41,234	\$0.1283	C H 1%	
<b>Lorazepam</b>					
Inj 2 mg per ml, 1 ml				H 1%	
Inj 4 mg per ml, 1 ml				H 1%	
<b>Lormetazepam</b>					
Tab 1 mg	31,050	\$3,219	\$0.1037 *	C H 1%	
<b>Maprotiline Hydrochloride</b>					
Tab 25 mg	55,224	\$13,839	\$0.2506	C H 1%	
Tab 75 mg	2,627	\$1,840	\$0.7003	C H 1%	
<b>Metoclopramide hydrochloride</b>					
Inj 5 mg per ml, 2 ml ampoule	216,568	\$97,456	\$0.4500	C H 1%	
Oral liq 5 mg per 5 ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Mianserin hydrochloride</b>					
Tab 30 mg				H 1%	
<b>Morphine sulphate</b>					
Cap long-acting 10 mg	3,285,522	\$558,539	\$0.1700	C H 1%	
Cap long-acting 30 mg	1,002,918	\$250,730	\$0.2500	C H 1%	
Cap long-acting 60 mg	319,923	\$172,758	\$0.5400	C H 1%	
Cap long-acting 100 mg	174,770	\$111,503	\$0.6380	C H 1%	
<u>Tab long-acting 10 mg</u>	708,610	\$136,762	\$0.1930	C H 1%	
<u>Tab long-acting 30 mg</u>	222,199	\$63,327	\$0.2850	C H 1%	
<u>Tab long-acting 60 mg</u>	103,803	\$58,130	\$0.5600	C H 1%	
<u>Tab long-acting 100 mg</u>	155,220	\$94,684	\$0.6100	C H 1%	
<b>Morphine tartrate</b>					
<u>Inj 80 mg per ml, 1.5 ml</u>	16,670	\$142,428	\$8.5440	C H 1%	
<b>Nicotine</b>					
Oral spray 1 mg per dose				H 1%	Access restrictions apply.
Soln for inhalation 15 mg cartridge				H 1%	Access restrictions apply.
<b>Nitrazepam</b>					
Tab 5 mg	388,701	\$20,290	\$0.0522	C H 1%	
<b>Nortriptyline hydrochloride</b>					
<u>Tab 10 mg</u>	11,295,161	\$363,704	\$0.0322	C H 1%	
<u>Tab 25 mg</u>	8,541,407	\$335,934	\$0.0393	C H 1%	
<b>Ondansetron</b>					
<u>Tab 4 mg</u>	1,963,626	\$131,956	\$0.0672	C H 1%	
<u>Tab 8 mg</u>	591,448	\$56,424	\$0.0954	C H 1%	
<b>Ondansetron hydrochloride</b>					
Inj 2 mg per ml, 2 ml				H 1%	

sole supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
<b>Ondansetron hydrochloride</b>					
Inj 2 mg per ml, 4 ml				H 1%	
<b>Oxycodone hydrochloride</b>					
Inj 1 mg per ml, 100 ml bag				H 1%	
<b>Paliperidone</b>					
Inj 100 mg syringe	10,206	\$4,440,835	\$435.1200 #	+ C H 1%	Depot injection. Special Authority restrictions may apply. Training requirements may apply.
Inj 150 mg syringe	11,408	\$4,963,849	\$435.1200 #	+ C H 1%	Depot injection. Special Authority restrictions may apply. Training requirements may apply.
Inj 25 mg syringe	675	\$131,119	\$194.2500 #	+ C H 1%	Depot injection. Special Authority restrictions may apply. Training requirements may apply.
Inj 50 mg syringe	2,068	\$562,393	\$271.9500 #	+ C H 1%	Depot injection. Special Authority restrictions may apply. Training requirements may apply.
Inj 75 mg syringe	4,437	\$1,585,873	\$357.4200 #	+ C H 1%	Depot injection. Special Authority restrictions may apply. Training requirements may apply.
<b>Paracetamol</b>					
Suppos 25 mg				H 1%	
Suppos 50 mg				H 1%	
<b>Paroxetine</b>					
Tab 20 mg	10,400,813	\$464,604	\$0.0447	C H 1%	Tablet must be scored
<b>Pericyazine</b>					
Tab 10 mg	150,273	\$66,796	\$0.4445	C H 1%	
Tab 2.5 mg	242,636	\$30,305	\$0.1249	C H 1%	
<b>Pimozide</b>					
Tab 2 mg or less				C H 1%	Not currently listed in the Pharmaceutical Schedule
Tab 4 mg or more				C H 1%	Not currently listed in the Pharmaceutical Schedule
<b>Pramipexole hydrochloride</b>					
Tab 0.25 mg	849,384	\$61,156	\$0.0720	C H 1%	
Tab 1 mg	113,828	\$27,763	\$0.2439	C H 1%	
<b>Primidone</b>					
Tab 25 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Tab 50 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
<b>Prochlorperazine</b>					
Tab 3 mg buccal	334,845	\$39,980	\$0.1194	C H 1%	
<b>Propofol</b>					
<u>Inj 10 mg per ml, 100 ml vial</u>				H 10%	Note there may be a preference for an EDTA containing product.
<u>Inj 10 mg per ml, 20 ml vial</u>				H 10%	Note there may be a preference for an EDTA containing product.
<u>Inj 10 mg per ml, 50 ml vial</u>				H 10%	Note there may be a preference for an EDTA containing product.
<b>Risperidone</b>					
Inj 25 mg per 2 ml	4,901	\$666,438	\$135.9800	C H 1%	Depot injection. Special Authority restrictions may apply. Training requirements may apply.
Inj 37.5 mg per 2 ml	5,830	\$1,041,879	\$178.7100	C H 1%	Depot injection. Special Authority restrictions may apply. Training requirements may apply.
Inj 50 mg per 2 ml	8,105	\$1,763,324	\$217.5600	C H 1%	Depot injection. Special Authority restrictions may apply. Training requirements may apply.

sole supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
<b>Ropinirole hydrochloride</b>						
Tab 1 mg	889,322	\$44,466	\$0.0500		C H 1%	
Tab 2 mg	404,379	\$31,218	\$0.0772		C H 1%	
Tab 250 mcg	1,224,424	\$34,039	\$0.0278		C H 1%	
Tab 5 mg	46,451	\$7,669	\$0.1651		C H 1%	
<b>Ropivacaine hydrochloride with fentanyl</b>						
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag					H 1%	
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag					H 1%	
<b>Sertraline</b>						
Tab 50 mg	8,750,213	\$296,545	\$0.0339		C H 1%	
Tab 100 mg	3,671,334	\$214,149	\$0.0583		C H 1%	
<b>Sucrose</b>						
Oral liq 25%					H 1%	
<b>Sumatriptan</b>						
Inj 12 mg per ml, 0.5 ml	41,410	\$883,482	\$21.3350		C H 1%	Price should include autoinjector
Tab 100 mg	290,523	\$134,309	\$0.4623		C H 1%	
Tab 50 mg	889,014	\$217,275	\$0.2444		C H 1%	
<b>Tetrabenazine</b>						
Tab 25 mg	116,005	\$94,357	\$0.8134		C H 1%	
<b>Tetracaine [amethocaine] hydrochloride</b>						
Gel 4%					H 1%	Special Authority restrictions may apply.
<b>Tolcapone</b>						
Tab 100 mg	149,498	\$198,085	\$1.3250		C H 1%	
<b>Triazolam</b>						
Tab 125 mcg	1,743,623	\$88,925	\$0.0510 *		C H 1%	
Tab 250 mcg	1,480,208	\$60,689	\$0.0410 *		C H 1%	
<b>Zopiclone</b>						
Tab 7.5 mg					H 1%	Tablets should be scored. Preference for pack size of 100 tablets or less.
<b>Zuclopenthixol Acetate</b>						
Inj 50mg per ml, 2 ml					H 1%	
<b>Zuclopenthixol Decanoate</b>						
Inj 200 mg per ml	25,488	\$100,932	\$3.9600		C H 1%	
Inj 500 mg per ml					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
<b>Zuclopenthixol hydrochloride</b>						
Tab 10 mg	164,343	\$51,686	\$0.3145		C H 1%	

**Oncology Agents and Immunosuppressants**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
<b>Abiraterone acetate</b>						
Tab 250 mg	606,074	\$21,597,399	\$35.6349#	+	C H 1%	Special Authority restrictions may apply.
<b>Anagrelide hydrochloride</b>						
Cap 0.5 mg	94,118				PCT C H 1%	This is currently a cost-brand source product.
<b>Azathioprine</b>						
Inj 50 mg					H 1%	
Tab 50 mg	3,811,006	\$403,204	\$0.1058		C H 1%	
Tab 25 mg	142,502	\$13,766	\$0.0966		C H 1%	
<b>Bendamustine</b>						
Inj 100 mg vial					PCT H 1%	
Inj 25 mg vial					PCT H 1%	
<u>sole supply</u>						

# =rebate \* =part charge @ =ASP + =patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Oncology Agents and Immunosuppressants**

Chemical Name	Units	Cost	Unit Subsidy	DV	Limit	Comments
Line Item						
<b>Bortezomib</b>						
Inj 3.5 mg				+PCT	H 1%	
<b>Busulfan</b>						
Inj 6 mg per ml, 10 ml				PCT	H 1%	
Tab 2 mg				PCT	H 1%	
<b>Calcium folinate</b>						
Inj 3 mg				PCT	H 1%	
Inj 300 mg - 350 mg				PCT	H 1%	Units and subsidy shown are per 300 mg injection
Inj 50 mg				PCT	H 1%	
Inj 100 mg				PCT	H 1%	
Inj 1 g				PCT	H 1%	
Tab 15 mg				PCT	H 1%	
<b>Capecitabine</b>						
<u>Tab 150 mg</u>	151,277	\$28,112	\$0.1858		C H 1%	
<u>Tab 500 mg</u>	749,153	\$388,810	\$0.5190		C H 1%	
<b>Dacarbazine</b>						
Inj 200 mg				PCT	H 1%	
<b>Doxorubicin</b>						
Inj 10 mg				PCT	H 1%	
Inj 50 mg				PCT	H 1%	
Inj 100 mg				PCT	H 1%	
<b>Etoposide</b>						
Inj 20 mg per ml, 5 ml				PCT	H 1%	
Cap 50 mg				PCT	H 1%	
Cap 100 mg				PCT	H 1%	
<b>Fludarabine phosphate</b>						
<u>Inj 50 mg</u>				PCT	H 1%	
<b>Fluorouracil sodium</b>						
Inj 50 mg per ml, 50 ml				PCT	H 1%	
<b>Gemcitabine hydrochloride</b>						
Inj 200 mg				PCT	H 1%	
Inj 1 g				PCT	H 1%	
<b>Mercaptopurine</b>						
Tab 50 mg				PCT	H 1%	
<b>Mesna</b>						
Inj 100 mg per ml, 4 ml				PCT	H 1%	
Inj 100 mg per ml, 10 ml				PCT	H 1%	
Tab 400 mg				PCT	H 1%	
Tab 600 mg				PCT	H 1%	
<b>Methotrexate</b>						
<u>Inj 25 mg per ml, 2 ml</u>				PCT	H 1%	
<u>Inj 25 mg per ml, 20 ml</u>				PCT	H 1%	
<b>Mitomycin C</b>						
<u>Inj 5 mg</u>				PCT	H 1%	
<b>Octreotide (somatostatin analogue)</b>						
LAR 10 mg pre-filled syringe	312	\$553,020	\$1,772.5000 #	+	C H 1%	Special Authority restrictions may apply.
LAR 20 mg pre-filled syringe	2,032	\$4,792,980	\$2,358.7500 #	+	C H 1%	Special Authority restrictions may apply.
LAR 30 mg pre-filled syringe	1,871	\$5,521,789	\$2,951.2500 #	+	C H 1%	Special Authority restrictions may apply.
<b>Pemetrexed</b>						
Powder for infusion, 100 mg				PCT	H 1%	Special Authority restrictions may apply.
Powder for infusion, 500 mg				PCT	H 1%	Special Authority restrictions may apply.

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Oncology Agents and Immunosuppressants**

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Chemical Name</b>					
Line Item					
<b>Temozolomide</b>					
Cap 100 mg	19,579	\$157,415	\$8.0400	C H 1%	
Cap 140 mg	348	\$3,898	\$11.2000	C H 1%	
Cap 20 mg	16,392	\$59,995	\$3.6600	C H 1%	
Cap 250 mg	835	\$16,166	\$19.3600	C H 1%	
Cap 5 mg	6,798	\$13,868	\$2.0400	C H 1%	
<b>Vincristine sulphate</b>					
Inj 1 mg per ml, 1 ml				PCT H 1%	
Inj 1 mg per ml, 2 ml				PCT H 1%	

**Respiratory System and Allergies**

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Chemical Name</b>					
Line Item					
<b>Beclomethasone Dipropionate</b>					
Metered aqueous nasal spray, 50 mcg per dose	3,571,000	\$41,959	\$0.0118 *	C H 1%	
Metered aqueous nasal spray, 100 mcg per dose	10,408,800	\$128,028	\$0.0123 *	C H 1%	
<b>Bee venom allergy treatment</b>					
Maintenance kit - 6 vials 120 mcg freeze dried venom with diluent	14	\$3,990	\$285.0000	C H 1%	
Treatment kit - 1 vial 550 mcg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml	556	\$169,580	\$305.0000	C H 1%	
<b>Caffeine citrate</b>					
Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml				H 1%	
Oral liq 20 mg per ml (10 mg base per ml)	11,150	\$6,623	\$0.5940	C H 1%	
<b>Cetirizine hydrochloride</b>					
Tab 10 mg	35,022,044	\$353,723	\$0.0101	C H 1%	
<b>Chlorpheniramine Maleate</b>					
Inj 10 mg per ml				H 1%	
Oral liq 2 mg per 5 ml	2,727,884	\$43,973	\$0.0161	C H 1%	
<b>Dextrochlorpheniramine Maleate</b>					
Oral liq 2 mg per 5 ml	10,625	\$188	\$0.0177 *	C H	Funding restrictions may apply.
Tab 2 mg	146,045	\$7,375	\$0.0505 *	C H	Funding restrictions may apply.
<b>Ipratropium bromide</b>					
<u>Nebuliser soln. 250 mcg per ml. 1 ml</u>	41,210	\$6,903	\$0.1675	C H 1%	
<u>Nebuliser soln. 250 mcg per ml. 2 ml</u>	125,978	\$22,172	\$0.1760	C H 1%	
<b>Loratadine</b>					
<u>Oral liq 1 mg per ml</u>	21,471,186	\$384,764	\$0.0179	C H 1%	
<u>Tab 10 mg</u>	29,461,627	\$377,109	\$0.0128	C H 1%	
<b>Montelukast</b>					
<u>Tab 10 mg</u>	584,127	\$117,871	\$0.2018	C H 1%	
<u>Tab 4 mg</u>	173,180	\$32,471	\$0.1875	C H 1%	
<u>Tab 5 mg</u>	173,675	\$34,115	\$0.1964	C H 1%	
<b>Oxymetazoline hydrochloride</b>					
Aqueous nasal spray 0.25 mg per ml				H 1%	
Aqueous nasal spray 0.5 mg per ml				H 1%	
<b>Paper wasp venom</b>					
Inj 550 mcg vial with diluent	99	\$30,195	\$305.0000	C H 1%	Special Authority restrictions may apply.
Treatment kit - 6 vials 120 mcg freeze dried venom, with diluent			\$305.0000	C H 1%	Special Authority restrictions may apply.
<b>Pholcodine</b>					
Oral liq 1 mg per ml				H 1%	
<b>Promethazine hydrochloride</b>					
<u>Inj 25 mg per ml. 2 ml</u>	9,033	\$28,075	\$3.1080	C H 1%	
<u>sole supply</u>					

#=-rebate \*=-part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Respiratory System and Allergies**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
<b>Pseudoephedrine Hydrochloride</b>						
Tab 60 mg				H 1%		
<b>Sodium chloride</b>						
Aqueous nasal spray isotonic				H 1%		
Nebuliser soln, 7%	903,240	\$235,845	\$0.2611	C H 1%		
<b>Sodium Cromoglycate</b>						
Nasal spray, 4%				H 1%		
<b>Talc</b>						
Powder				H 1%		
Soln (slurry) 100 mg per ml, 50 ml				H 1%		
<b>Theophylline</b>						
Oral liq 80 mg per 15 ml	69,095	\$2,142	\$0.0310	C H 1%		
Tab long-acting 250 mg	607,053	\$130,577	\$0.2151	C H 1%		
<b>Xylometazoline hydrochloride</b>						
Aqueous nasal spray 0.05%				H 1%		
Aqueous nasal spray 0.1%				H 1%		
Nasal drops 0.05%				H 1%		
Nasal drops 0.1%				H 1%		
<b>Yellow jacket wasp venom</b>						
Inj 550 mcg vial with diluent			\$305.0000	C H 1%	Special Authority restrictions may apply.	
Treatment kit - 6 vials 120 mcg freeze dried venom with diluent			\$305.0000	C H 1%	Special Authority restrictions may apply.	

**Sensory Organs**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
<b>Acetylcholine chloride</b>						
Inj 20 mg vial with diluent				H 1%		
<b>Aciclovir</b>						
<u>Eye oint 3%</u>	22,725	\$75,346	\$3.3156	C H 1%		
<b>Betaxolol hydrochloride</b>						
Eye drops 0.25%	17,185	\$40,557	\$2.3600	C H 1%	For products containing BAK, PHARMAC reserves the right to list a BAK or preservative free product for a restricted market.	
Eye drops 0.5%	7,210	\$10,815	\$1.5000	C H 1%	For products containing BAK, PHARMAC reserves the right to list a BAK or preservative free product for a restricted market.	
<b>Brimonidine Tartrate with Timolol Maleate</b>						
Eye drops 0.2% with timolol maleate 0.5%	215,725	\$798,183	\$3.7000 #	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Unit subsidy expressed as "per	
<b>Brinzolamide</b>						
Eye drops 1%	333,270	\$651,210	\$1.9540	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml.	
<b>Carbomer</b>						
Ophthalmic gel 0.3%	118,695	\$32,641	\$0.2750	C H 1%	Special Authority restrictions may apply	
<b>Chloramphenicol</b>						
Eye drops 0.5%	1,511,880	\$148,164	\$0.0980	C H 1%	Single dose presentation would not be a DV Pharmaceutical. Unit subsidy expressed as "per ml"	
<u>Eye oint 1%</u>	558,820	\$346,468	\$0.6200	C H 1%		

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Sensory Organs**

<b>Chemical Name</b>					<b>DV</b>	
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>Limit</b>	<b>Comments</b>
<b>Dexamethasone</b>						
Eye drops 0.1%	175,945	\$158,351	\$0.9000 #	C H	1%	
Eye oint 0.1%	23,601	\$39,514	\$1.6743 #	C H	1%	
<b>Disodium edetate</b>						
Inj 150 mg per ml, 100 ml				H	1%	
Inj 150 mg per ml, 20 ml				H	1%	
<b>Docusate sodium</b>						
Ear drops 0.5%				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Fluorescein</b>						
Inj 10%, 5 ml vial				H	1%	Preference for vial.
<b>Fluorometholone</b>						
Eye drops 0.1%	139,830	\$86,415	\$0.6180	C H	1%	Unit subsidy expressed as "per ml"
<b>Gentamicin Sulphate</b>						
Eye drops 0.3%	1,220	\$2,782	\$2.2800	C H	1%	Single dose presentation would not be a DV Pharmaceutical
<b>Macrogol 400 and propylene glycol</b>						
Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml	336,164	\$60,231	\$0.1792	C H	1%	Special Authority restrictions may apply.
<b>Olopatadine</b>						
Eye drops 5%	664,890	\$1,329,780	\$2.0000 #	C H	1%	
<b>Polyvinyl alcohol</b>						
<u>Eye drops 1.4%</u>	357,675	\$62,475	\$0.1747	C H	1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml
<u>Eye drops 3%</u>	213,645	\$52,414	\$0.2453	C H	1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml
<b>Retinol palmitate</b>						
Eye oint 138 mcg per g	33,975	\$25,821	\$0.7600	C H	1%	
<b>Sodium Cromoglycate</b>						
Eye drops 2%	255,300	\$43,401	\$0.1700	C H	1%	
<b>Sodium fusidate [fusidic acid]</b>						
Eye drops 1%	309,575	\$278,618	\$0.9000	C H	1%	
<b>Sodium hyaluronate [hyaluronic acid]</b>						
Eye drops 1 mg per ml	288,360	\$634,392	\$2.2000 #	C H	1%	Special Authority restrictions may apply.
<u>Inj 10 mg per ml, 0.85 ml syringe</u>				H	1%	Please note in tender bid if product is dispersive or cohesive viscoelastic
<u>Inj 14 mg per ml, 0.55 ml syringe</u>				H	1%	Please note in tender bid if product is dispersive or cohesive viscoelastic
<u>Inj 14 mg per ml, 0.85 ml syringe</u>				H	1%	Please note in tender bid if product is dispersive or cohesive viscoelastic
<u>Inj 23 mg per ml, 0.6 ml syringe</u>				H	1%	Please note in tender bid if product is dispersive or cohesive viscoelastic
<b>Sodium hyaluronate [hyaluronic acid] with chondroitin sulphate</b>						
<u>Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe</u>				H	1%	Please note in tender bid if product is dispersive or cohesive viscoelastic
<u>Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe</u>				H	1%	Please note in tender bid if product is dispersive or cohesive viscoelastic
<u>Inj 30 mg with chondroitin sulphate 40 mg per ml, 0.75 ml syringe</u>				H	1%	Please note in tender bid if product is dispersive or cohesive viscoelastic

sole supply

#=rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Sensory Organs**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Tetracaine [amethocaine] hydrochloride</b>						
Eye drops 0.5%, single dose					H 1%	
Eye drops 1%, single dose					H 1%	
<b>Tobramycin</b>						
Eye drops 0.3%	2,285	\$5,246	\$2.2960		C H 1%	
<b>Tropicamide</b>						
Eye drops 0.5%	1,665	\$794	\$0.4767		C H 1%	Single unit dose presentation (individual vial) would not count towards DV limit.
Eye drops 1%	7,185	\$4,148	\$0.5773		C H 1%	Single unit dose presentation (individual vial) would not count towards DV limit.